These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 27442667)
1. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity. Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma. Matsushima H; Adachi T; Hidaka M; Yamashita M; Hamada T; Fukui S; Tanaka T; Imamura H; Yoshino K; Kugiyama T; Kitasato A; Hara T; Soyama A; Kobayashi K; Sumida Y; Kuroki T; Eguchi S Anticancer Res; 2022 Jun; 42(6):3133-3141. PubMed ID: 35641261 [TBL] [Abstract][Full Text] [Related]
3. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study. Sakamoto T; Kishino M; Murakami Y; Miyatani K; Hanaki T; Shishido Y; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Fujiwara Y Medicine (Baltimore); 2024 May; 103(21):e38292. PubMed ID: 38788030 [TBL] [Abstract][Full Text] [Related]
4. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma. Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K Anticancer Res; 2021 Mar; 41(3):1629-1639. PubMed ID: 33788759 [TBL] [Abstract][Full Text] [Related]
6. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma. Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991 [TBL] [Abstract][Full Text] [Related]
7. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Matsumoto I; Tanaka M; Shirakawa S; Shinzeki M; Toyama H; Asari S; Goto T; Yamashita H; Ishida J; Ajiki T; Fukumoto T; Shimokawa M; Ku Y Ann Surg Oncol; 2015 Jul; 22(7):2408-15. PubMed ID: 25487967 [TBL] [Abstract][Full Text] [Related]
8. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update. Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639 [TBL] [Abstract][Full Text] [Related]
9. Why the Treatment Sequence Matters: Interplay Between Chemotherapy Cycles Received, Cumulative Dose Intensity, and Survival in Resected Early-stage Pancreas Cancer. Wu VS; Elshami M; Stitzel HJ; Lee JJ; Hue JJ; Kyasaram RK; Hardacre JM; Ammori JB; Winter JM; Selfridge JE; Mohamed A; Chakrabarti S; Bajor D; Mahipal A; Ocuin LM Ann Surg; 2023 Oct; 278(4):e677-e684. PubMed ID: 37071769 [TBL] [Abstract][Full Text] [Related]
10. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988 [TBL] [Abstract][Full Text] [Related]
11. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios. Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488 [TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193 [TBL] [Abstract][Full Text] [Related]
13. [Surgical therapy of pancreatic cancer - 5 years survival]. Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155 [TBL] [Abstract][Full Text] [Related]
14. Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? Tani M; Kawai M; Terasawa H; Ina S; Hirono S; Uchiyama K; Yamaue H J Surg Oncol; 2006 May; 93(6):485-90. PubMed ID: 16615151 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma. Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600 [TBL] [Abstract][Full Text] [Related]
16. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446 [TBL] [Abstract][Full Text] [Related]
17. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma? Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254 [TBL] [Abstract][Full Text] [Related]
18. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis. Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114 [TBL] [Abstract][Full Text] [Related]
19. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371 [TBL] [Abstract][Full Text] [Related]
20. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Group of Pancreatobiliary Surgery in Japan. Satoi S; Murakami Y; Motoi F; Sho M; Matsumoto I; Uemura K; Kawai M; Kurata M; Yanagimoto H; Yamamoto T; Mizuma M; Unno M; Kinoshita S; Akahori T; Shinzeki M; Fukumoto T; Hashimoto Y; Hirono S; Yamaue H; Honda G; Kwon M Pancreas; 2016 Aug; 45(7):1003-9. PubMed ID: 26692442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]